Aktis Oncology, Inc.
corporate_fare Company Profile
Aktis Oncology, Inc. (NASDAQ:AKTS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 24 items for AKTS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for AKTS spans 8-K, 4, 10-Q, 10-K.
Recent high-impact activity:
- Aktis Q3 Loss Widens to $29.9M; $492.9M Cash Funds Plan Into 2029
- Aktis Oncology Starts Second Phase 1b Trial for AKY-2519 in Lung and Other Solid Tumors
- COO Ron-Bigger Shulamit Exercises Options and Sells $1.39M in Aktis Stock
- Aktis Oncology's AKY-2519 Radioconjugate Shows Robust Tumor Uptake, Limited Normal Tissue Exposure in Early Data
- Aktis Oncology Reports Strong Q1 Results with $538.5M Cash, Extending Runway into 2029 Post-IPO
Short Interest & Short Volume
16.02 days to coverFINRA reported short interest of 4,425,903 shares in AKTS as of the October 30, 2026 settlement, a 2.6% increase from the prior period — about 16.0 days to cover at its recent average daily volume. On November 20, 2026, 73.9% of AKTS volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.